Experimental Drug Shows Promise in Advanced Gastric Cancer Trial

Clinical trials from AstraZeneca indicate that its therapeutic candidate Sora-Ve decreased mortality risk by 42 percent among patients receiving second-line gastric cancer treatment. The drug offers potential options for individuals diagnosed with advanced stomach cancer who have exhausted standard care.